Medulloblastoma

Journal of Child Neurology

Volumn 24, Issue 11, 2009, Pages 1418-1430

  Dhall, Girish ^a  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

Medulloblastoma; Notch; Sonic hedgehog; Treatment and late effects; Wingless

Indexed keywords

ANTINEOPLASTIC AGENT; APC PROTEIN; BETA CATENIN; CARBOPLATIN; CARMUSTINE; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; HYDROXYUREA; IFOSFAMIDE; LOMUSTINE; MESSENGER RNA; METHOTREXATE; N ACETYLASPARTIC ACID; NOTCH RECEPTOR; PREDNISONE; PROCARBAZINE; SONIC HEDGEHOG PROTEIN; TAURINE; THIOTEPA; VINCRISTINE; WNT1 PROTEIN;

BASAL CELL NEVUS SYNDROME; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHILDHOOD CANCER; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DEVELOPMENTAL DISORDER; DISEASE ASSOCIATION; DRUG MEGADOSE; EVENT FREE SURVIVAL; GENE MUTATION; HIGH RISK PATIENT; HUMAN; INFECTION; INTELLECTUAL IMPAIRMENT; INTELLIGENCE QUOTIENT; LUMBAR PUNCTURE; MAINTENANCE THERAPY; MEDULLOBLASTOMA; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TURCOT SYNDROME;

BRAIN; BRAIN NEOPLASMS; CHILD; HUMANS; MEDULLOBLASTOMA;

EID: 70449098988     PISSN: 08830738     EISSN: 17088283     Source Type: Journal    
DOI: 10.1177/0883073809341668     Document Type: Conference Paper

References (81)

1. Wright J. Neurocytoma or neuroblastoma, a kind of tumor not generally recognized. J Exp Med. 1910;12(4):556-561.
2. Bailey P., Cushing H. Medulloblastoma cerebelli. Arch Neurol Psychiatr. 1925;14:192-224.
3. CBTRUS, Central Brain Tumor Registry of the United States (2007 - 2008). Primary brain tumors in the United States, Statistical Report (2000-2004), Years of Data Collected. Chicago: Author.
4. Chan AW, Tarbell NJ, Black PM, et al. Adult medulloblastoma: Prognostic factors and patterns of relapse. Neurosurgery. 2000;47(3):623-631; discussion 631-632.
5. Wang Z., Sutton LN, Cnaan A., et al. Proton MR spectroscopy of pediatric cerebellar tumors. AJNR Am J Neuroradiol. 1995;16(9):1821-1833.
6. Girard N., Wang ZJ, Erbetta A., et al. Prognostic value of proton MR spectroscopy of cerebral hemisphere tumors in children. Neuroradiology. 1998;40(2):121-125.
7. Hwang YF, Huang TY, Hwang SL, Kwan AL, Howng SL Differentiation among metastatic brain tumors, radiation necroses, and brain abscesses using proton magnetic resonance spectroscopy. Kaohsiung J Med Sci. 2004;20(9):437-442.
8. Chernov MF, Hayashi M., Izawa M., et al. Multivoxel proton MRS for differentiation of radiation-induced necrosis and tumor recurrence after gamma knife radiosurgery for brain metastases. Brain Tumor Pathol. 2006;23(1):19-27.
9. Panigrahy A., Krieger MD, Gonzalez-Gomez I., et al. Quantitative short echo time 1H-MR spectroscopy of untreated pediatric brain tumors: preoperative diagnosis and characterization. AJNR Am J Neuroradiol. 2006;27(3):560-572.
10. Gururangan S., Hwang E., Herndon JE 2nd, Fuchs H., George T., Coleman RE [18F]fluorodeoxyglucose-positron emission tomography in patients with medulloblastoma. Neurosurgery. 2004;55(6):1280-1288; discussion 1288-1289.
11. Giangaspero F., Eberhart C., Haapasalo H., Pietsch T., Wiestler OD, Ellison DW Medulloblastoma. In: Louis DN, Ohgaki H, Wiestler D, Cavenee WK, eds. WHO Classification of Tumors of the Central Nervous System. Lyon: IARC Press; 2007:132-146.
12. Rutkowski S., Bode U., Deinlein F., et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med. 2005;352(10):978-986.
13. Brown HG, Kepner JL, Perlman EJ, et al. "Large cell/ anaplastic" medulloblastomas: A Pediatric Oncology Group Study. J Neuropathol Exp Neurol. 2000;59(10):857-865.
14. Helton KJ, Fouladi M., Boop FA, et al. Medullomyoblastoma: A radiographic and clinicopathologic analysis of six cases and review of the literature. Cancer. 2004;101(6):1445-1454.
15. Kalimo H., Paljarvi L., Ekfors T., Pelliniemi LJ Pigmented primitive neuroectodermal tumor with multipotential differentiation in cerebellum (pigmented medullomyoblastoma). A case with light- and electron-microscopic, and immunohistochemical analysis. Pediatr Neurosci. 1987;13(4):188-195.
16. Ellison D. Classifying the medulloblastoma: Insights from morphology and molecular genetics. Neuropathol Appl Neurobiol. 2002;28(4):257-282.
17. Katsetos CD, Liu HM, Zacks SI Immunohistochemical and ultrastructural observations on Homer Wright (neuroblastic) rosettes and the "pale islands" of human cerebellar medulloblastomas. Hum Pathol. 1988;19(10):1219-1227.
18. Gailani MR, Bale SJ, Leffell DJ, et al. Developmental defects in Gorlin syndrome related to a putative tumor suppressor gene on chromosome 9. Cell. 1992;69(1):111-117.
19. Schofield D., West DC, Anthony DC, Marshal R., Sklar J. Correlation of loss of heterozygosity at chromosome 9q with histological subtype in medulloblastomas. Am J Pathol. 1995;146(2):472-480.
20. Stone DM, Hynes M., Armanini M., et al. The tumour-suppressor gene patched encodes a candidate receptor for Sonic hedgehog. Nature. 1996;384(6605):129-134.
21. Goldowitz D., Hamre K. The cells and molecules that make a cerebellum. Trends Neurosci. 1998;21(9):375-382.
22. Raffel C. Medulloblastoma: Molecular genetics and animal models. Neoplasia. 2004;6(4):310-322.
23. Gilbertson RJ Medulloblastoma: Signaling a change in treatment. Lancet Oncol. 2004;5(4):209-218.
24. Pietsch T., Waha A., Koch A., et al. Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of Drosophila patched. Cancer Res. 1997;57(11):2085-2088.
25. Zurawel RH, Allen C., Chiappa S., et al. Analysis of PTCH/SMO/SHH pathway genes in medulloblastoma. Genes Chromosomes Cancer. 2000;27(1):44-51.
26. Lam CW, Xie J., To KF, et al. A frequent activated smoothened mutation in sporadic basal cell carcinomas. Oncogene. 1999;18(3):833-836.
27. Oro AE, Higgins KM, Hu Z., Bonifas JM, Epstein EH Jr, Scott MP Basal cell carcinomas in mice overexpressing sonic hedgehog. Science. 1997;276(5313):817-821.
28. Taylor MD, Liu L., Raffel C., et al. Mutations in SUFU predispose to medulloblastoma. Nat Genet. 2002;31(3):306-310.
29. Hamilton SR, Liu B., Parsons RE, et al. The molecular basis of Turcot's syndrome. N Engl J Med. 1995;332(13):839-847.
30. Baeza N., Masuoka J., Kleihues P., Ohgaki H. AXIN1 mutations but not deletions in cerebellar medulloblastomas. Oncogene. 2003;22(4):632-636.
31. Eberhart CG, Tihan T., Burger PC Nuclear localization and mutation of beta-catenin in medulloblastomas. J Neuropathol Exp Neurol. 2000;59(4):333-337.
32. Huang H., Mahler-Araujo BM, Sankila A., et al. APC mutations in sporadic medulloblastomas. Am J Pathol. 2000;156(2):433-437.
33. Koch A., Waha A., Tonn JC, et al. Somatic mutations of WNT/wingless signaling pathway components in primitive neuroectodermal tumors. Int J Cancer. 2001;93(3):445-449.
34. Sjolund J., Manetopoulos C., Stockhausen MT, Axelson H. The Notch pathway in cancer: Differentiation gone awry. Eur J Cancer. 2005;41(17):2620-2629.
35. Fan X., Mikolaenko I., Elhassan I., et al. Notch1 and notch2 have opposite effects on embryonal brain tumor growth. Cancer Res. 2004;64(21):7787-7793.
36. Lasky JL, Wu H. Notch signaling, brain development, and human disease. Pediatr Res. 2005;57(5 pt 2):104R-109R.
37. Yarden Y., Sliwkowski MX Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127-137.
38. Gajjar A., Hernan R., Kocak M., et al. Clinical, histopathologic, and molecular markers of prognosis: Toward a new disease risk stratification system for medulloblastoma. J Clin Oncol. 2004;22(6):984-993.
39. Gilbertson RJ, Perry RH, Kelly PJ, Pearson AD, Lunec J. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res. 1997;57(15):3272-3280.
40. Chang CH, Housepian EM, Herbert C. Jr. An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology. 1969;93(6):1351-1359.
41. Gajjar A., Chintagumpala M., Ashley D., et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): Long-term results from a prospective, multicentre trial. Lancet Oncol. 2006;7(10):813-820.
42. Packer RJ, Gajjar A., Vezina G., et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006;24(25):4202-4208.
43. Packer RJ, Rood BR, MacDonald TJ Medulloblastoma: Present concepts of stratification into risk groups. Pediatr Neurosurg. 2003;39(2):60-67.
44. Rutkowski S., von Bueren A., von Hoff K., et al. Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT-91. Clin Cancer Res. 2007;13(9):2651-2657.
45. Ellison DW, Onilude OE, Lindsey JC, et al. Beta-catenin status predicts a favorable outcome in childhood medulloblastoma: The United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol. 2005;23(31):7951-7957.
46. Cuneo H., Rand C. Medulloblastoma. Brain Tumors of Childhood. Los Angeles, CA: Charles C Thomas; 1952:21-42.
47. Evans AE, Jenkin RD, Sposto R., et al. The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg. 1990;72(4):572-582.
48. Thomas PR, Deutsch M., Kepner JL, et al. Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol. 2000;18(16):3004-3011.
49. Mulhern RK, Kepner JL, Thomas PR, Armstrong FD, Friedman HS, Kun LE Neuropsychologic functioning of survivors of childhood medulloblastoma randomized to receive conventional or reduced-dose craniospinal irradiation: A Pediatric Oncology Group study. J Clin Oncol. 1998;16(5):1723-1728.
50. Packer RJ, Sutton LN, Elterman R., et al. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg. 1994;81(5):690-698.
51. Packer RJ, Goldwein J., Nicholson HS, et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study. J Clin Oncol. 1999;17(7):2127-2136.
52. Ris MD, Packer R., Goldwein J., Jones-Wallace D., Boyett JM Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: A Children's Cancer Group study. J Clin Oncol. 2001;19(15):3470-3476.
53. Goldwein JW, Radcliffe J., Johnson J., et al. Updated results of a pilot study of low dose craniospinal irradiation plus chemotherapy for children under five with cerebellar primitive neuroectodermal tumors (medulloblastoma). Int J Radiat Oncol Biol Phys. 1996;34(4):899-904.
54. Wolden SL, Dunkel IJ, Souweidane MM, et al. Patterns of failure using a conformal radiation therapy tumor bed boost for medulloblastoma. J Clin Oncol. 2003;21(16):3079-3083.
55. Zeltzer PM, Boyett JM, Finlay JL, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: Conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol. 1999;17(3):832-845.
56. Taylor RE, Bailey CC, Robinson KJ, et al. Outcome for patients with metastatic (M2-3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy. Eur J Cancer. 2005;41(5):727-734.
57. Miralbell R., Fitzgerald TJ, Laurie F., et al. Radiotherapy in pediatric medulloblastoma: Quality assessment of Pediatric Oncology Group Trial 9031. Int J Radiat Oncol Biol Phys. 2006;64(5):1325-1330.
58. Jakacki R., Burger PC, Zhou T., et al. E. Potcome for metastatic (M+) medulloblastoma treated with carboplatin during craniospinal radiotherapy followed by cyclophosphamide and vincristine: Preliminary results of COG 99701. In: Grunberg SM, ed. American Society of Clinical Oncology. Chicago, IL: 2007: 79s.
59. Stiller CA, Bunch KJ Brain and spinal tumours in children aged under two years: Incidence and survival in Britain, 1971-85. Br J Cancer Suppl. 1992;18:S50-S53.
60. Duffner PK, Cohen ME, Myers MH, Heise HW Survival of children with brain tumors: SEER Program, 1973-1980. Neurology. 1986;36(5):597-601.
61. van Eys J., Cangir A., Coody D., Smith B. MOPP regimen as primary chemotherapy for brain tumors in infants. J Neurooncol. 1985;3(3):237-243.
62. Ater JL, van Eys J., Woo SY, Moore B. 3rd, Copeland DR, Bruner J. MOPP chemotherapy without irradiation as primary postsurgical therapy for brain tumors in infants and young children. J Neurooncol. 1997;32(3):243-252.
63. Duffner PK, Horowitz ME, Krischer JP, et al. The treatment of malignant brain tumors in infants and very young children: An update of the Pediatric Oncology Group experience. Neuro Oncol. 1999;1(2):152-161.
64. Duffner PK, Horowitz ME, Krischer JP, et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med. 1993;328(24):1725-1731.
65. Dupuis-Girod S., Hartmann O., Benhamou E., et al. Will high dose chemotherapy followed by autologous bone marrow transplantation supplant cranio-spinal irradiation in young children treated for medulloblastoma? J Neurooncol. 1996;27(1):87-98.
66. Kuehl J. Delayed radiation therapy after post-operative chemotherapy in children less than 3 years of age with medulloblastoma: Results of the trial HIT-SSK'87 and preliminary results of the pilot trial HIT-SSK'92. Med Pediatr Oncol. 1995;25:250.
67. White L., Kellie S., Gray E., et al. Postoperative chemotherapy in children less than 4 years of age with malignant brain tumors: Promising initial response to a VETOPEC-based regimen. A Study of the Australian and New Zealand Children's Cancer Study Group (ANZCCSG). J Pediatr Hematol Oncol. 1998;20(2):125-130.
68. Geyer JR, Zeltzer PM, Boyett JM, et al. Survival of infants with primitive neuroectodermal tumors or malignant ependymomas of the CNS treated with eight drugs in 1 day: A report from the Childrens Cancer Group. J Clin Oncol. 1994;12(8):1607-1615.
69. Geyer JR, Sposto R., Jennings M., et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: A report from the Children's Cancer Group. J Clin Oncol. 2005;23(30):7621-7631.
70. Strother DR, Kepner JL, Aronin P., et al. Preliminary results of the Pediatric Oncology Group baby brain two protocol. 8th International Symposium on Pediatric Neuro-Oncology; May 6-9, 1998; Rome.
71. Grill J., Sainte-Rose C., Jouvet A., et al. Treatment of medulloblastoma with postoperative chemotherapy alone: An SFOP prospective trial in young children. Lancet Oncol. 2005;6(8):573-580.
72. Chi SN, Gardner S., Ji L., et al. Newly diagnosed high-risk malignant brain tumors with leptomeinigeal dissemination in young children: A final update on Head Start II regimen A2 intensified with high-dose methotrexate. J Clin Oncol. 2007;25(18S):539s.
73. Chi SN, Gardner SL, Levy AS, et al. Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma. J Clin Oncol. 2004;22(24):4881-4887.
74. Dhall G., Grodman H., Ji L., et al. Outcome of children less than three years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy on the "Head Start" I and II protocols. Pediatr Blood Cancer. 2008;50(6):1169-1175.
75. Hartsell WF, Gajjar A., Heideman RL, et al. Patterns of failure in children with medulloblastoma: Effects of preirradiation chemotherapy. Int J Radiat Oncol Biol Phys. 1997;39(1):15-24.
76. Bowers DC, Gargan L., Weprin BE, et al. Impact of site of tumor recurrence upon survival for children with recurrent or progressive medulloblastoma. J Neurosurg. 2007;107(1 suppl):5-10.
77. Dunkel IJ, Boyett JM, Yates A., et al. High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group. J Clin Oncol. 1998;16(1):222-228.
78. Guruangan S., Dunkel IJ, Goldman S., et al. Myeloablative chemotherapy with autologous bone marrow rescue in young children with recurrent malignant brain tumors. J Clin Oncol. 1998;16(7):2486-2493.
79. Gururangan S., Krauser J., Watral MA, et al. Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma. Neuro Oncol. 2008;10(5):745-751.
80. Shih CS, Hale GA, Gronewold L., et al. High-dose chemotherapy with autologous stem cell rescue for children with recurrent malignant brain tumors. Cancer. 2008;112(6):1345-1353.
81. Sung KW, Yoo KH, Cho EJ, et al. High-dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high-risk or relapsed medulloblastoma or supratentorial primitive neuroectodermal tumor. Pediatr Blood Cancer. 2007;48(9):408-415.